Lange Rael T, Brickell Tracey A, Lippa Sara M, French Louis M
a Defense and Veterans Brain Injury Center , Bethesda , MD , USA.
J Clin Exp Neuropsychol. 2015;37(8):853-62. doi: 10.1080/13803395.2015.1064864. Epub 2015 Aug 6.
The purpose of this study was to examine the clinical utility of three recently developed validity scales (Validity-10, NIM5, and LOW6) designed to screen for symptom exaggeration using the Neurobehavioral Symptom Inventory (NSI). Participants were 272 U.S. military service members who sustained a mild, moderate, severe, or penetrating traumatic brain injury (TBI) and who were evaluated by the neuropsychology service at Walter Reed Army Medical Center within 199 weeks post injury. Participants were divided into two groups based on the Negative Impression Management scale of the Personality Assessment Inventory: (a) those who failed symptom validity testing (SVT-fail; n = 27) and (b) those who passed symptom validity testing (SVT-pass; n = 245). Participants in the SVT-fail group had significantly higher scores (p<.001) on the Validity-10, NIM5, LOW6, NSI total, and Personality Assessment Inventory (PAI) clinical scales (range: d = 0.76 to 2.34). Similarly high sensitivity, specificity, positive predictive power (PPP), and negative predictive (NPP) values were found when using all three validity scales to differentiate SVT-fail versus SVT-pass groups. However, the Validity-10 scale consistently had the highest overall values. The optimal cutoff score for the Validity-10 scale to identify possible symptom exaggeration was ≥19 (sensitivity = .59, specificity = .89, PPP = .74, NPP = .80). For the majority of people, these findings provide support for the use of the Validity-10 scale as a screening tool for possible symptom exaggeration. When scores on the Validity-10 exceed the cutoff score, it is recommended that (a) researchers and clinicians do not interpret responses on the NSI, and (b) clinicians follow up with a more detailed evaluation, using well-validated symptom validity measures (e.g., Minnesota Multiphasic Personality Inventory-2 Restructured Form, MMPI-2-RF, validity scales), to seek confirmatory evidence to support an hypothesis of symptom exaggeration.
本研究的目的是检验最近开发的三种效度量表(效度-10、NIM5和LOW6)的临床效用,这些量表旨在使用神经行为症状量表(NSI)筛查症状夸大情况。研究参与者为272名美国军人,他们遭受了轻度、中度、重度或穿透性创伤性脑损伤(TBI),并在受伤后199周内由沃尔特里德陆军医疗中心的神经心理学服务部门进行了评估。根据人格评估量表的负面印象管理量表,参与者被分为两组:(a)症状效度测试未通过组(SVT-未通过;n = 27)和(b)症状效度测试通过组(SVT-通过;n = 245)。SVT-未通过组的参与者在效度-10、NIM5、LOW6、NSI总分和人格评估量表(PAI)临床量表上的得分显著更高(p<.001)(范围:d = 0.76至2.34)。在使用所有三种效度量表区分SVT-未通过组和SVT-通过组时,也发现了同样高的敏感性、特异性、阳性预测力(PPP)和阴性预测力(NPP)值。然而,效度-10量表始终具有最高的总体值。用于识别可能症状夸大的效度-10量表的最佳临界分数为≥19(敏感性 =.59,特异性 =.89,PPP =.74,NPP =.80)。对于大多数人来说,这些发现为使用效度-10量表作为可能症状夸大的筛查工具提供了支持。当效度-10的分数超过临界分数时,建议:(a)研究人员和临床医生不要解释NSI上的反应,(b)临床医生使用经过充分验证的症状效度测量方法(例如,明尼苏达多相人格问卷-2修订版,MMPI-2-RF,效度量表)进行更详细的评估,以寻求支持症状夸大假设的确证证据。